These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1420919)

  • 1. Penetration of macromolecules into contracted blood clot.
    Matveyev MYu ; Domogatsky SP
    Biophys J; 1992 Sep; 63(3):862-3. PubMed ID: 1420919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
    Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
    Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo penetration of experimentally produced clots by monoclonal antibodies.
    McEvoy FJ; Edgell TA; Webbon PM; Gaffney PJ
    Thromb Haemost; 2000 Jun; 83(6):882-6. PubMed ID: 10896242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinogen uptake by thrombi: effect of thrombus age.
    Coleman RE; Harwig SS; Harwig JF; Siegel BA; Welch MJ
    J Nucl Med; 1975 May; 16(5):370-3. PubMed ID: 1194988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affects of hirudin and heparin on the binding of new fibrin to the thrombus in t-PA treated rabbits.
    Agnelli G; Pascucci C; Cosmi B; Nenci GG
    Thromb Haemost; 1991 Nov; 66(5):592-7. PubMed ID: 1839474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proceedings: 71. Changes of fibrinogen turn over rate by fibrinolysis (author's transl)].
    Sugie I; Hishikawa Y; Nitta H
    Nihon Seirigaku Zasshi; 1973; 35(8):411. PubMed ID: 4799272
    [No Abstract]   [Full Text] [Related]  

  • 8. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
    Cadroy Y; Horbett TA; Hanson SR
    J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
    Andrew M; Brooker L; Leaker M; Paes B; Weitz J
    Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
    Kawakami K; Takahashi A; Yoshimoto T
    No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary thrombus composition: links with inflammation, platelet and endothelial markers.
    Sadowski M; Ząbczyk M; Undas A
    Atherosclerosis; 2014 Dec; 237(2):555-61. PubMed ID: 25463088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
    Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
    Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel and emerging therapies: thrombus-targeted fibrinolysis.
    Lippi G; Mattiuzzi C; Favaloro EJ
    Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of immune complexes on coagulation and fibrinolysis in vivo.
    Simpson JG; Robertson AJ; Stalker AL
    Bibl Anat; 1973; 12():260-6. PubMed ID: 4790360
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on metabolism of urokinase and mechanism of thrombolysis by urokinase.
    Ueno T; Kobayashi N; Maekawa T
    Thromb Haemost; 1979 Oct; 42(3):885-94. PubMed ID: 505403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concepts of clot lysis.
    Francis CW; Marder VJ
    Annu Rev Med; 1986; 37():187-204. PubMed ID: 2939790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodilution modulates the time of onset and rate of fibrinolysis in human and rabbit plasma.
    Nielsen VG
    J Heart Lung Transplant; 2006 Nov; 25(11):1344-52. PubMed ID: 17097499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.